# PEN-866 in Patients With Advanced Solid Malignancies

> **NCT03221400** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tarveda Therapeutics** · enrollment: 340 (estimated)

## Conditions studied

- Carcinoma
- Endometrial Adenocarcinoma
- Neoplasms
- Squamous Cell Carcinoma of the Anus
- Adenocarcinoma of the Pancreas
- Advanced Cancer
- Solid Tumor
- Solid Carcinoma
- Squamous Cell Carcinoma of the Cervix
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Vulva
- Squamous Cell Carcinoma of the Penis
- Gastric Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** PEN-866 Sodium
- **DRUG:** fluorouracil
- **DRUG:** Folinic acid
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03221400
- **Lead sponsor:** Tarveda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-29
- **Primary completion:** 2023-01
- **Final completion:** 2023-06
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221400, "PEN-866 in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03221400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*